JP2015501845A5 - - Google Patents

Download PDF

Info

Publication number
JP2015501845A5
JP2015501845A5 JP2014547462A JP2014547462A JP2015501845A5 JP 2015501845 A5 JP2015501845 A5 JP 2015501845A5 JP 2014547462 A JP2014547462 A JP 2014547462A JP 2014547462 A JP2014547462 A JP 2014547462A JP 2015501845 A5 JP2015501845 A5 JP 2015501845A5
Authority
JP
Japan
Prior art keywords
alkyl
group
independently
compound
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014547462A
Other languages
English (en)
Japanese (ja)
Other versions
JP6300730B2 (ja
JP2015501845A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/069637 external-priority patent/WO2013090664A1/en
Publication of JP2015501845A publication Critical patent/JP2015501845A/ja
Publication of JP2015501845A5 publication Critical patent/JP2015501845A5/ja
Application granted granted Critical
Publication of JP6300730B2 publication Critical patent/JP6300730B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014547462A 2011-12-16 2012-12-14 ベツリンの誘導体 Expired - Fee Related JP6300730B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161576448P 2011-12-16 2011-12-16
US61/576,448 2011-12-16
PCT/US2012/069637 WO2013090664A1 (en) 2011-12-16 2012-12-14 Derivatives of betulin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018000027A Division JP2018065867A (ja) 2011-12-16 2018-01-04 ベツリンの誘導体

Publications (3)

Publication Number Publication Date
JP2015501845A JP2015501845A (ja) 2015-01-19
JP2015501845A5 true JP2015501845A5 (enExample) 2016-01-28
JP6300730B2 JP6300730B2 (ja) 2018-03-28

Family

ID=48613199

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014547462A Expired - Fee Related JP6300730B2 (ja) 2011-12-16 2012-12-14 ベツリンの誘導体
JP2018000027A Withdrawn JP2018065867A (ja) 2011-12-16 2018-01-04 ベツリンの誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018000027A Withdrawn JP2018065867A (ja) 2011-12-16 2018-01-04 ベツリンの誘導体

Country Status (38)

Country Link
US (6) US20150218142A1 (enExample)
EP (2) EP3263580A1 (enExample)
JP (2) JP6300730B2 (enExample)
KR (1) KR101953869B1 (enExample)
CN (2) CN107501383A (enExample)
AR (1) AR089285A1 (enExample)
AU (1) AU2012352110B2 (enExample)
BR (1) BR112014014769A2 (enExample)
CA (1) CA2859030C (enExample)
CL (1) CL2014001585A1 (enExample)
CO (1) CO6970600A2 (enExample)
CR (1) CR20140301A (enExample)
CY (1) CY1119422T1 (enExample)
DK (1) DK2791103T3 (enExample)
DO (1) DOP2014000121A (enExample)
EA (2) EA201790923A1 (enExample)
ES (1) ES2644578T3 (enExample)
HR (1) HRP20171512T1 (enExample)
HU (1) HUE034877T2 (enExample)
IL (1) IL233081A (enExample)
JO (1) JO3387B1 (enExample)
LT (1) LT2791103T (enExample)
MA (1) MA35833B1 (enExample)
ME (1) ME02895B (enExample)
MX (1) MX360679B (enExample)
PE (1) PE20141788A1 (enExample)
PH (3) PH12014501362B1 (enExample)
PL (1) PL2791103T3 (enExample)
PT (1) PT2791103T (enExample)
RS (1) RS56373B1 (enExample)
SG (1) SG11201402707PA (enExample)
SI (1) SI2791103T1 (enExample)
SM (1) SMT201700466T1 (enExample)
TW (2) TW201730202A (enExample)
UA (1) UA116978C2 (enExample)
UY (1) UY34523A (enExample)
WO (1) WO2013090664A1 (enExample)
ZA (1) ZA201404135B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3387B1 (ar) 2011-12-16 2019-03-13 Glaxosmithkline Llc مشتقات بيتولين
CN103242413B (zh) * 2012-02-08 2015-08-26 江西青峰药业有限公司 Lupane三萜系衍生物及其药学用途
MA38182A1 (fr) * 2012-12-14 2018-04-30 Glaxosmithkline Llc Compositions pharmaceutiques a action prolongée pur une utilisation dans le traitement ou la prévention d'infections par le virus de l’immunodéficience humaine (vih)
US9637516B2 (en) 2012-12-31 2017-05-02 Hetero Research Foundation Betulinic acid proline derivatives as HIV inhibitors
US20170129916A1 (en) 2014-06-26 2017-05-11 Hetero Research Foundation Novel betulinic proline imidazole derivatives as hiv inhibitors
SG11201702379TA (en) 2014-09-26 2017-04-27 Glaxosmithkline Ip No 2 Ltd Long acting pharmaceutical compositions
US9969767B2 (en) * 2014-11-14 2018-05-15 VIIV Healthcare UK (No.5) Limited Oxolupene derivatives
CN107250151A (zh) * 2014-11-14 2017-10-13 Viiv保健英国第五有限公司 扩展的桦木酸类似物
MA40886B1 (fr) 2015-02-09 2020-03-31 Hetero Research Foundation Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih
US10370405B2 (en) 2015-03-16 2019-08-06 Hetero Labs Limited C-3 novel triterpenone with C-28 amide derivatives as HIV inhibitors
CA2993758A1 (en) * 2015-07-28 2017-02-02 Glaxosmithkline Intellectual Property (No.2) Limited Betuin derivatives for preventing or treating hiv infections
WO2017017609A1 (en) 2015-07-28 2017-02-02 Glaxosmithkline Intellectual Property (No.2) Limited Betuin derivatives for preventing or treating hiv infections
AU2016327169A1 (en) 2015-09-24 2018-04-12 Glaxosmithkline Intellectual Property (No.2) Limited Compounds with hiv maturation inhibitory activity
EP3405474A1 (en) 2016-01-20 2018-11-28 Glaxosmithkline Intellectual Property (No. 2) Limited Amine derivatives of lupanes with hiv maturation inhibitory activity
WO2018042332A1 (en) 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
WO2018042331A1 (en) 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
WO2018044853A1 (en) * 2016-08-31 2018-03-08 Viiv Healthcare Conpany Combinations and uses and treatments thereof
WO2018044838A1 (en) * 2016-08-31 2018-03-08 Viiv Healthcare Company Combinations and uses and treatments thereof
WO2019150300A1 (en) 2018-02-02 2019-08-08 Glaxosmithkline Intellectual Property (No.2) Limited Crystalline forms of 4-(((3ar,5ar,5br,7ar,9s,11ar,11br,13as)-3a-((r)-2-((4-chlorobenzyl)(2-(dimethylamino)ethyl)amino)-1-hydroxyethyl)-1-isopropyl-5a,5b,8,8,11a-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a,11b,12,13,13a-octadecahydro-2h-cyclopenta[a]chrysen-9-yl)oxy)-2,2-dimethyl-4-oxobutanoic acid
WO2019186342A1 (en) 2018-03-27 2019-10-03 Glaxosmithkline Intellectual Property (No.2) Limited Ionic liquid salts of 4-(((3ar,5ar,5br,7ar,9s,11ar,11br,13as)-3a-((r)-2-((4-chlorobenzyl)(2-(dimethylamino)ethyl)amino)-1-hydroxyethyl)-1-isopropyl-5a,5b,8,8,11a-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a,11b,12,13,13a-octadecahydro-2h-cyclopenta[a]chrysen-9-yl)oxy)-2,2-dimethyl-4-oxobutanoic acid
EP4321164A3 (en) 2018-04-24 2024-04-17 ViiV Healthcare UK (No.5) Limited Compounds with hiv maturation inhibitory activity
KR101909885B1 (ko) * 2018-05-25 2018-10-19 김예원 살리드로사이드 또는 베툴린을 이용한 뇌수막종 개선용 조성물
PL237998B1 (pl) 2018-05-28 2021-06-28 Narodowy Inst Lekow Fosfonowe pochodne kwasu 3-karboksyacylobetulinowego, sposób ich otrzymywania oraz ich zastosowanie

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB427857A (en) 1934-08-02 1935-05-01 Newsum Sons & Company Ltd H A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5358721A (en) 1992-12-04 1994-10-25 Alza Corporation Antiviral therapy
EP1292562A1 (en) 2000-05-23 2003-03-19 Univerzita palackeho V Olomouci Triterpenoid derivatives
IL157940A0 (en) 2001-03-19 2004-03-28 Ono Pharmaceutical Co Drugs containing triazaspiro [5.5] undecane derivatives as the active ingredient
US7163700B2 (en) 2001-07-31 2007-01-16 Capricorn Pharma, Inc. Amorphous drug beads
US20080206161A1 (en) 2002-10-25 2008-08-28 Dov Tamarkin Quiescent foamable compositions, steroids, kits and uses thereof
ES2312856T3 (es) 2002-12-13 2009-03-01 Smithkline Beecham Corporation Compuestos heterociclicos como antagonistas de ccr5.
ES2298627T3 (es) 2002-12-13 2008-05-16 Smithkline Beecham Corporation Compuestos de ciclopropilo como antagonistas de ccr5.
AU2003300952A1 (en) 2002-12-13 2004-07-09 Smithkline Beecham Corporation Indane compounds as ccr5 antagonists
CN1744899A (zh) 2002-12-13 2006-03-08 史密丝克莱恩比彻姆公司 作为ccr5拮抗剂的哌啶衍生物
DE60322423D1 (de) 2002-12-13 2008-09-04 Smithkline Beecham Corp Pyrrolidin- und azetidinverbindungen alsccr5-antagonisten
ES2311755T3 (es) 2002-12-13 2009-02-16 Smithkline Beecham Corporation Compuestos de ciclohexilo como antagonistas de ccrs.
US20050142205A1 (en) 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
WO2005112929A2 (en) 2004-05-20 2005-12-01 Cornell Research Foundation, Inc. Anti-hiv-1 activity of betulinol derivatives
TW200628161A (en) * 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
CN101142227A (zh) * 2004-11-12 2008-03-12 帕纳克斯医药公司 新颖的桦木醇衍生物、其制备和其用途
WO2006105356A2 (en) 2005-03-29 2006-10-05 Regents Of The University Of Minnesota Methods of manufacturing bioactive 3-esters of betulinic aldehyde and betulinic acid
TWI457136B (zh) 2005-04-04 2014-10-21 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
WO2006117666A2 (en) 2005-04-29 2006-11-09 Pfizer Inc. Dosage forms, pharmaceutical compositions and methods for sub-tenon delivery
US20070197646A1 (en) 2006-02-21 2007-08-23 Achillion Pharmaceuticals, Inc. Substituted taraxastanes useful for treating viral infections
FI121468B (fi) 2006-06-07 2010-11-30 Valtion Teknillinen Betuliiniperäiset yhdisteet antimikrobisina aineina
HUE068406T2 (hu) 2006-06-23 2024-12-28 Janssen Sciences Ireland Unlimited Co A TMC278 vizes szuszpenziója
WO2008127364A2 (en) 2006-10-13 2008-10-23 Myriad Genetics, Inc. Antiviral compounds and use thereof
AR063546A1 (es) 2006-11-03 2009-01-28 Panacos Pharmaceuticals Inc DERIVADOS DE TRITERPENO, METODOS PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN Y SU USO EN LA FABRICACION DE MEDICAMENTOS PARA EL TRATAMIENTO DE INFECCIoN POR EL VIRUS VIH.
WO2009082819A1 (en) 2008-01-03 2009-07-09 Virochem Pharma Inc. Novel lupane derivatives
CN101977924A (zh) * 2008-01-03 2011-02-16 Viro化学制药公司 新的c-21-酮基羽扇烷衍生物、其制备方法和应用
DE102008037025C5 (de) 2008-08-08 2016-07-07 Jesalis Pharma Gmbh Verfahren zur Herstellung kristalliner Wirkstoff-Mikropartikel bzw. einer Wirkstoffpartikel-Festkörperform
US8778990B2 (en) * 2008-11-04 2014-07-15 Trustees Of Dartmouth College Betulinic acid derivatives and methods of use thereof
CZ301318B6 (cs) 2008-11-13 2010-01-13 Univerzita Palackého v Olomouci 2-Deoxyglykosidy triterpenoidu, zpusob jejich prípravy a jejich použití jako lécivo
EP3210603A1 (en) 2008-12-11 2017-08-30 Shionogi & Co., Ltd Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
US8802727B2 (en) * 2009-07-14 2014-08-12 Hetero Research Foundation, Hetero Drugs Limited Pharmaceutically acceptable salts of betulinic acid derivatives
US9067966B2 (en) 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
FR2948132B1 (fr) 2009-07-20 2011-08-26 Inst Francais Textile & Habillement Association de produits cationiques et anioniques naturels comme liant pour support textile
EA201290632A1 (ru) 2010-02-11 2013-03-29 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Производные бетулина
TWI577377B (zh) 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
WO2013020245A1 (en) 2011-08-08 2013-02-14 Glaxosmithkline Llc Carbonyl derivatives of betulin
WO2013020246A1 (en) * 2011-08-08 2013-02-14 Glaxosmithkline Llc Methylene derivatives of betulin
WO2013091144A1 (en) 2011-12-21 2013-06-27 Glaxosmithkline Llc Propenoate derivatives of betulin
ES2584684T3 (es) 2011-12-14 2016-09-28 Glaxosmithkline Llc Derivados de propenoato de betulina
JO3387B1 (ar) * 2011-12-16 2019-03-13 Glaxosmithkline Llc مشتقات بيتولين
CN104844679B (zh) * 2011-12-16 2017-03-01 葛兰素史克有限责任公司 白桦脂醇的衍生物
WO2014035945A1 (en) 2012-08-28 2014-03-06 Glaxosmithkline Llc Pharmaceutical compositions
MA38182A1 (fr) 2012-12-14 2018-04-30 Glaxosmithkline Llc Compositions pharmaceutiques a action prolongée pur une utilisation dans le traitement ou la prévention d'infections par le virus de l’immunodéficience humaine (vih)
SG11201702379TA (en) 2014-09-26 2017-04-27 Glaxosmithkline Ip No 2 Ltd Long acting pharmaceutical compositions

Similar Documents

Publication Publication Date Title
JP2015501845A5 (enExample)
KR102583013B1 (ko) 항-hiv 화합물
AU2017312102B2 (en) Therapeutic compounds useful for the prophylactic or therapeutic treatment of an HIV virus infection
JP2022160589A (ja) Ｈｉｖを治療するためのトール様受容体の調節因子
EP3356355B1 (en) Compounds and combinations for the treatment of hiv
NZ716350A (en) Tricyclic benzoxaborole compounds and uses thereof
KR20240011880A (ko) N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도
HRP20240501T1 (hr) Derivati pirido[2,3-d]pirimidina kao inhibitori replikacije virusa humane imunodeficijencije
De Clercq Human viral diseases: what is next for antiviral drug discovery?
JP2020500866A5 (enExample)
RU2018137389A (ru) Гетероциклические амиды, полезные в качестве модуляторов
ME02570B (me) Farmaceutska kompozicija koja sadrži ne-nukleozidni inhibitor reverzne transkriptaze
JP2013216697A5 (enExample)
JP2011173928A5 (enExample)
JP2019500387A5 (enExample)
JP2019511542A5 (enExample)
JP2011510077A5 (enExample)
JP2009525265A5 (enExample)
AU2009223064B2 (en) Use of 4'-Thio-2'-Deoxynucleosides as Anti Orthopoxvirus Agents
EP3600332B1 (en) Hiv post-exposure prophylaxis
HRP20211895T1 (hr) Novi spojevi
RU2018105343A (ru) Производные бетулина для предупреждения или лечения ВИЧ-инфекций
RU2018105352A (ru) Производные бетулина для предупреждения или лечения ВИЧ-инфекций
RU2018112958A (ru) Соединения с ингибирующей созревание ВИЧ активностью
US20220265689A1 (en) Hiv pre-exposure prophylaxis